Overview

Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
0
Participant gender:
All
Summary
An outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. Here, we hypothesize that experimentally-induced dilation of intracranial arteries using intravenous infusion of levcromakalim (a potent vasodilator) induces cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Danish Headache Center
Collaborator:
Novartis
Treatments:
Cromakalim
Criteria
Inclusion Criteria:

- Participant has provided informed consent prior to initiation of any study-specific
activities/procedures.

- Age ≥18 years upon entry into screening.

- History of migraine without aura for ≥12 months with a frequency of 1-5 migraine
attacks per month before screening according to the International Headache Society
(IHS) Classification ICHD-3 (Headache Classification Committee of the International
Headache Society, 2018), based on medical records and/or patient self-report.

Exclusion Criteria:

- History of any primary headache disorder other than migraine without aura, or
tension-type headache with a frequency of ≥5 headache days per month before screening
according to the International Headache Society (IHS) Classification ICHD-3 (Headache
Classification Committee of the International Headache Society, 2018), based on
medical records and/or patient self-report.

- History of any secondary headache disorder before screening according to the
International Headache Society (IHS) Classification ICHD-3 (Headache Classification
Committee of the International Headache Society, 2018) based on medical records and/or
patient self-report.

- Intake of prophylactic migraine medication within ≤30 days or 5 plasma half-lives
(whichever is longer) prior to screening.

- Prior intake of therapies targeting the CGRP signaling pathway, including anti-CGRP
ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, and small
molecule CGRP receptor antagonists.

- The participant is at risk of self-harm or harm to others as evidenced by past
suicidal behavior.

- History or evidence of any other clinically significant disorder, condition, or
disease (with the exception of those outlined above) that, in the opinion of the
investigator will pose a risk to participant safety or interfere with the study
evaluation, procedures or completion.

- Female participants of childbearing potential with a positive pregnancy test assessed
at screening or day 1 by a urine pregnancy test.

- Female participants who are pregnant or breastfeeding or plan to become pregnant or
breastfeed during participation in the study.

- Evidence of current pregnancy or breastfeeding per participant self-report or medical
records.

- Participants likely to not be available to complete all protocol-required study visits
or procedures, and/or to comply with all required study procedures to the best of the
participants' and investigator's knowledge.